ABBV · 10-Q · 2026Q3 · Full report

Oncology Market Position

AbbVie Inc. · 2026-11-03 · Importance 51 · Surprise 64

Venclexta net revenues increased 11% in the third quarter and 10% in the first nine months of 2026, primarily driven by increased demand. Elahere grew 31% and 23%, respectively, on increased demand, while Epkinly net revenues increased 58% and 55% at constant currency. These product trends indicate continued demand growth across several oncology brands, while Imbruvica faced lower demand and pricing pressure as described in the neuroscience market discussion.

Key facts

• In February 2026, the FDA approved Venclexta with acalabrutinib for previously untreated adults with chronic lymphocytic leukemia. source
• In May 2026, the European Commission authorized an expanded Venclyxto label for combination use with acalabrutinib, with or without obinutuzumab, and with Imbruvica for previously untreated adults with chronic lymphocytic leukemia. source
• In January 2026, AbbVie reported that the Phase 3 EPCORE DLBCL-1 trial of Epkinly versus investigator’s-choice chemoimmunotherapy in adults with relapsed/refractory diffuse large B-cell lymphoma did not demonstrate statistically significant overall-survival improvement. source
• In June 2026, AbbVie announced that the Phase 3 EPCORE DLBCL-4 trial of Epkinly plus lenalidomide versus rituximab, gemcitabine, and oxaliplatin in adults with relapsed/refractory DLBCL after at least one prior therapy met its primary endpoint, improving progression-free survival. source
• In July 2026, the European Commission granted marketing authorization for Tepkinly with lenalidomide and rituximab for adults with relapsed/refractory follicular lymphoma. source
• In October 2026, AbbVie announced positive topline Phase 3 EPCORE DLBCL-2 results for fixed-duration Epkinly plus R-CHOP versus R-CHOP alone in newly diagnosed DLBCL, with statistically significant and clinically meaningful improvement in progression-free survival. source
• In May 2026, the FDA approved Decnupaz (pivekimab sunirine-pvzy) for adults with blastic plasmacytoid dendritic cell neoplasm. source
• In September 2026, AbbVie announced positive topline Phase 3 CERVINO results for etentamig versus investigator-selected available therapies in triple-class-exposed adults with relapsed/refractory multiple myeloma, demonstrating significant progression-free-survival improvements. source